RTP Mobile Logo
Using the Morbidity and Mortality Conference Model to Explore and Improve Community-Based Oncology Care (Video Program)
Released July 2017

Highlights from video interviews with clinical investigators Drs Heather Wakelee, J Randolph Hecht and Michael Birrer along with community oncologists Drs Maria Picton, Estelamari Rodriguez, Gigi Qiqi Chen and Margaret Deutsch using the morbidity and mortality conference model to gain insight into how patients who recently died of non-small cell lung cancer, colorectal cancer and ovarian cancer were cared for during their metastatic disease course and how specific approaches used align with evidence-based guidelines. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, radiation oncologists and other healthcare providers involved in the treatment of lung, colorectal and ovarian cancers.

    The clinical care of patients with incurable solid tumors is a challenging dilemma that practicing oncologists confront on a daily basis. Despite the existence of evidence-based treatment guidelines, many areas of inconsistency persist within academic and community settings. Given the heightened emphasis across oncology on the provision of high-quality care, endeavors designed to fill the resulting performance gaps are greatly needed.

    The morbidity and mortality conference model traditionally evaluates disease management and potential areas for quality improvement. This program uses the model to gain insight into how patients who recently died of non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and ovarian cancer (OC) were cared for during their metastatic disease course and how specific approaches used align with evidence-based guidelines. Featuring information on the latest clinical and research developments along with expert perspectives, this activity is designed to assist medical oncologists with the formulation of up-to-date strategies for the long-term care of patients with metastatic NSCLC, CRC and OC.


    • Identify opportunities to foster shared decision-making and heighten the engagement and satisfaction of patients and family members throughout the cancer care journey.
    • Evaluate the current variability in the integration of specific agents, regimens and therapeutic approaches into the care of patients with metastatic NSCLC, CRC and OC, and use the input of clinical investigators to formulate optimal treatment strategies.
    • Recall the scientific rationale for and emerging efficacy data with novel agents or therapeutic approaches in NSCLC and OC, and counsel appropriately selected patients about study participation.
    • Implement a plan of care to prevent and ameliorate toxicities associated with existing and investigational therapies used in the management of advanced CRC.
    • Recognize the benefits of early palliative care for patients with metastatic disease, and integrate this information, as appropriate, into current clinical treatment algorithms.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MorbidityMortality17/Video/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    LUNG CANCER FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Clinical Investigator

    Heather Wakelee, MD
    Associate Professor of Medicine
    Division of Oncology
    Stanford University School of Medicine
    Stanford Cancer Institute
    Stanford, California

    Consulting Agreements: ACEA Biosciences Inc, Genentech BioOncology, Helsinn Group, Peregrine Pharmaceuticals Inc, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech BioOncology, Gilead Sciences Inc, Lilly, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Xcovery; Grants: Clovis Oncology, Exelixis Inc, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company, Xcovery. 

    General Oncologists

    Maria Picton, MD
    Physicians East
    Greenville, North Carolina

    No relevant conflicts of interest to disclose.

    Estelamari Rodriguez, MD, MPH
    Medical Director, Thoracic Oncology
    Chair, Women’s Centered Care Network
    Mount Sinai Medical Center
    Comprehensive Cancer Center
    Miami Beach, Florida

    Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology; Speakers Bureau: Merck. 

    COLORECTAL CANCER FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Clinical Investigator

    J Randolph Hecht, MD
    Professor of Clinical Medicine
    Director, UCLA GI Oncology Program
    Carol and Saul Rosenzweig Chair in Cancer Therapies Development
    Santa Monica, California

    Consulting Agreements: Amgen Inc, Genentech BioOncology, Roche Laboratories Inc. 

    General Oncologists

    Gigi Qiqi Chen, MD
    Diablo Valley Oncology and Hematology Medical Group
    Pleasant Hill, California 

    Advisory Committee: Bayer HealthCare Pharmaceuticals; Speakers Bureau: Boehringer Ingelheim Pharmaceuticals Inc. 

    Margaret Deutsch, MD
    Clinical Associate — Medical Oncology
    Duke Cancer Institute
    Duke Cancer Center Raleigh
    Raleigh, North Carolina

    No relevant conflicts of interest to disclose.

    OVARIAN CANCER FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Clinical Investigator

    Michael Birrer, MD, PhD
    Director, UAB Comprehensive Cancer Center
    University of Alabama at Birmingham
    Birmingham, Alabama

    Advisory Committee: Acceleron Pharma, AstraZeneca Pharmaceuticals LP, ImmunoGen Inc, Merrimack Pharmaceuticals Inc, OXiGENE Inc, Roche Laboratories Inc, Sanofi Genzyme, Threshold Pharmaceuticals. 

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Genentech BioOncology and Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2017
    Expiration date: July 2018

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Metastatic wild-type nonsquamous non-small cell lung cancer (NSCLC)

  • Video overview (Dr Love): Key project findings
  • Optimal molecular testing algorithm for patients with metastatic nonsquamous lung cancer
  • KEYNOTE-024 trial evaluating pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score of 50% or greater
  • KEYNOTE-021 trial: Evaluating the addition of pembrolizumab to chemotherapy for advanced NSCLC
  • Finding meaning and satisfaction as an oncologist
  • A patient’s insight and perspective on the quality of care received
  • Hospice in end-of-life care and access to palliative care services for oncologists in community practice

Metastatic colorectal cancer (mCRC)

  • Use of anti-EGFR antibodies for RAS wild-type mCRC and impact of primary tumor location on the efficacy of anti-EGFR therapy
  • Efficacy of BRAF inhibitors in BRAF-mutated mCRC
  • Efficacy and tolerability of anti-PD-1/PD-L1 antibodies in patients with MSI-high mCRC
  • Case discussion: A 60-year-old woman who presents with abdominal pain and a large pelvic mass is diagnosed with right-sided, KRAS mutation-positive mCRC
  • Side effects and dose adjustments with regorafenib and TAS-102
  • End-of-life planning for patients with mCRC

Metastatic epithelial ovarian cancer (OC)

  • Importance of BRCA testing for all patients with OC and role of next-generation sequencing
  • Results of the Phase III ENGOT-OV16/NOVA trial of niraparib maintenance therapy for platinum-sensitive, recurrent OC
  • Benefits of early palliative care and psychological counseling
  • Effect of short-term goals on a patient’s will to live
  • Viewpoint on end-of-life care, including hospice